TY  - JOUR
AU  - Sepulveda-Sanchez, Juan Manuel
AU  - Vaz, Maria Angeles
AU  - Balaña, Carmen
AU  - Gil-Gil, Miguel
AU  - Reynes, Gaspar
AU  - Gallego, Oscar
AU  - Martinez-Garcia, Maria
AU  - Vicente, Elena
AU  - Quindos, Maria
AU  - Luque, Raquel
AU  - Ramos, Ana
AU  - Ruano, Yolanda
AU  - Perez-Segura, Pedro
AU  - Benavides, Manuel
AU  - Sanchez-Gomez, Pilar
AU  - Hernandez-Lain, Aurelio
PY  - 2017
DO  - 10.1093/neuonc/nox105
UR  - http://hdl.handle.net/10668/11264
T2  - Neuro-oncology
AB  - We conducted a multicenter, 2-stage, open-label, phase II trial to assess the efficacy and safety of dacomitinib in adult patients with recurrent glioblastoma (GB) and epidermal growth factor receptor gene (EGFR) amplification with or without variant...
LA  - en
PB  - Oxford University Press
KW  - EGFR
KW  - Dacomitinib
KW  - Glioblastoma
KW  - High-grade glioma
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Brain Neoplasms
KW  - ErbB Receptors
KW  - Female
KW  - Follow-Up Studies
KW  - Gene Amplification
KW  - Gene Expression Regulation, Neoplastic
KW  - Glioblastoma
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Prognosis
KW  - Quinazolinones
KW  - Signal Transduction
KW  - Survival Rate
TI  - Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
TY  - research article
VL  - 19
ER  -